Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus vaccine H5N1 - Daiichi Sankyo Biotech

Next Previous
Drug Profile

Influenza A virus vaccine H5N1 - Daiichi Sankyo Biotech

Alternative Names: Adsorbed cell culture-derived H5N1 influenza virus vaccine - Daiichi Sankyo Biotech; Cell culture-based pandemic influenza vaccine - Daiichi Sankyo Biotech; Cell-culture H5N1 flu vaccine - Daiichi Sankyo Biotech; H1N1 vaccine - Daiichi Sankyo Biotech; H5N1 vaccine - Daiichi Sankyo Biotech; KIB PCI; Pandemic influenza vaccine - Daiichi Sankyo Biotech; Precipitated influenza vaccine cell culture H5N1 strain - Daiichi Sankyo Biotech; VN 101

Latest Information Update: 31 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kitasato Daiichi Sankyo Vaccine
  • Developer Daiichi Sankyo Biotech
  • Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza A virus H5N1 subtype

Most Recent Events

  • 27 Mar 2020 Daiichi Sankyo and Kitasato Pharmaceutical Industry terminates an cooperative sales agreement for Influenza HA Vaccine
  • 07 Aug 2019 Influenza A virus vaccine H5N1 is not yet available for Influenza A virus H5N1 subtype (In adolescents, In children, In infants, Prevention) in Japan (IM)
  • 30 Nov 2017 Kitasato Daiichi Sankyo Vaccine has been acquired by Daiichi Sankyo Company
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top